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Abstract
The hematopoietic cell transplant (HCT) activity has grown significantly over the past two dec-
ades in both developing and developed countries. Many challenges arise in establishing new HCT
programs in developing countries, due to scarcity of resources and manpower in expertise in
HCT. While cost issues can potentially hinder establishment of new HCT programs in certain
regions, the focus on quality and value should be included in the general vision of leadership
before establishing an HCT program. The main challenge in most developing countries is the
lack of trained/qualified personnel, enormous start-up costs for a tertiary care center, and
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quality maintenance. Herein, we discuss the main challenges from a cost and quality perspec-
tive which occur at initiation of a new HCT program. We give real world examples of two devel-
oping countries that have recently started new HCT programs despite significant financial
constraints. We also portray recommendations from the Worldwide Network of Blood and Mar-
row Transplantation for levels of requirements for a new HCT program. We hope that this
review will serve as a general guide for new transplant program leadership with respect to
the concerns of balancing high quality with concurrently lowering costs.
 2017 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
Introduction
Hematopoietic cell transplantation (HCT) is curative for
many diseases including hematologic malignancies, bone
marrow failure syndromes, primary immunodeficiencies,
genetic conditions, hemoglobinopathies, and autoimmune
diseases [1]. Due to its curative potential and advances in
the supportive care, the mortality of allogeneic transplants
has decreased considerably over the past few decades [2],
therefore, HCT activity continues to increase exponentially
worldwide, including in the developing countries; however,
human development index and gross national income per
capita are observed to have associations with HCT activity
globally [3]. While HCT is potentially curative for many dis-
eases, it is an intensely resource requiring treatment modal-
ity which requires adequate capital for start-up costs, and
both HCT experts and governmental organizations are look-
ing for guidance for essentials for a new HCT which can be
tailored according to the needs of their countries. An HCT
program can be established at a reduced cost in a develop-
ing country given the financial restraints, but it should have
minimum quality standards which should ensure good ethi-
cal business principles, as well as have a keen focus on
patient safety and a vision of long term sustainability. This
paper will focus on two essential aspects of establishment
of a new HCT program–quality maintenance and cost reduc-
tion strategies; we hope that an analysis of the basic aspects
of quality and costs will help the nations without any HCT
program to establish HCT activity. Notably, one of the most
important aspects of new tertiary care center establishment
is lack of expertise (i.e., well trained personnel), however,
the detailed discussion of the human resource expertise is
beyond the scope of this paper.
Basics of costs and value in healthcare
The definitions in healthcare economics are important and
we will review them here first with a description of specific
examples in the field of HCT.
Value: How much usefulness or pleasure an
individual gets from a commodity or service
Value is still stable and subjective (utility). In the field of
HCT, value can be defined by many parameters. Patient
reported outcome measures have recently been considered
as a new benchmark for HCT survivorship studies [4]. This
variable can potentially infer the purest measurement of
value in HCT care. The traditional benchmarks of value in
HCT have been considered to be clinical outcomes, for
instance, progression free survival, overall survival, etc.
However, these outcome based value measures do not con-
tain any input from a patient, thereby, the transplant com-
munity is favoring patient reported outcome measures as
one of the key measures of success of an HCT and thereby,
an important and appropriate proxy for measuring value.
Price/cost
Cost and the (final) price are identical numbers (unless mar-
ket trends are being analyzed). Real cost should be adjusted
for inflation whenever evaluated (e.g., adjusted for 2017 US
$). In the field of HCT, cost measurement analyses have been
generally poor, since most of the studies only report the
direct costs for a fixed amount of time. Most medical institu-
tions lack transparency when it comes to reporting the actual
direct and indirect costs versus charges due to the existing
bylaws of their institutions. On average, an allogeneic trans-
plant costs around US$120,000–400,000 (adjusted to 2012)
for the first few months of transplant as reported in litera-
ture. For a similar duration of treatments, the costs of allo-
geneic transplant reported from developing countries are
US$12,500 (unadjusted), US$17,194 (unadjusted) and US
$31,500 (unadjusted) in Mexico, India, and Brazil respec-
tively [5–7]. Although these cost differences seem huge,
with a 10-fold difference in total costs of a procedure, it does
not account for important factors which impact clinical out-
comes, nor does it impact the ‘‘value” parameters from a
patient perspective. The average household income and
GDP per capita of developing countries is significantly differ-
ent than the developed countries, thus, in strict economic
sense, it may not be appropriate to compare the actual direct
cost estimates of countries with each other.
There is a paucity of published data when it comes to the
costs of establishing a new HCT center due to many factors.
The differences in governmental policies, vendor proce-
dures and the overall goal of establishment of a specialized
center (for profit or not-for-profit) are the main determi-
nants which can create considerable variation in the costs
incurred in establishing a program.
Competitive market: a marketplace where buyers
and sellers are equally informed
Medical business can never be a competitive market, as the
buyers (patients) and sellers (physicians) cannot have equal
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power of medical decision making. However, joint decision
making in all medical aspects including HCT is of utmost
importance, given its direct impact on clinical outcomes.
Basics of quality in healthcare
Quality in healthcare is defined as the level of value provided
by any healthcare organization or individual, and can be
assessed quantitatively or qualitatively. The overall aim of
healthcare provision is to utilize medical resources of high
quality to all who need them to alleviate the quality of life
as well as longevity. Quality measurement in healthcare is
the process of using data to evaluate the performance of
healthcare institutions, healthcare plans or healthcare pro-
viders counter to recognized quality standards.
Measuring the quality of healthcare is an essential step in
the process of improving healthcare quality of any special-
ized program, including HCT. Frequently, when the cost-
cutting strategies are employed, they affect the quality of
care, which eventually leads to poor and substandard out-
comes. Quality measurement can be used to improve an
HCT recipient’s healthcare by: (1) ensuring multiple check
points to patient safety, (2) preventing the overuse, under-
use, and misuse of healthcare services, and (3) identifying
what works in a particular healthcare setting, e.g., consider
endemic factors such as presence of tuberculosis in a
country.
Cost-control in HCT
For controlling costs of a specialized healthcare program, it
is necessary to firstly focus on minimal requirements for
adequate and sustainable functioning of the program. The
requirements have three levels as recommended by the
Worldwide Network for Blood and Marrow Transplantation
(WBMT) workshop (Table 1). Measures such as isolation
capacities, when added up at macroeconomic level, can
tremendously increase the annual initial costs of transplant
programs, however, the net benefit of such measures is
clearly demonstrated by improvement in survival due to
reduction in fatal invasive infections, as well as low trans-
mission of nosocomial microbes. The costs associated with
a single outbreak of a hospital acquired infection, e.g.,
methicillin-resistant Staphylococcus aureus or clostridium
difficile infections, can drive up the indirect and direct costs
of a program to astounding levels. Thus, it is preferred as a
Level I WBMT recommendation to have isolation facilities in
an HCT center. The Level II requirements are a preferred
obligation of a committed HCT center, and can help in
reduction of many HCT-related complications of an HCT
program. A classic consideration would be a high-
efficiency particulate air (HEPA) filter which can reduce
the risk of many infections, particularly tuberculosis, which
can be rapidly fatal in immunocompromised patients.
Level III indications for setting up an HCT unit include
optimal tertiary care facilities and state of the art outpa-
tient and inpatient facilities with HEPA filters. These are
not mandatory requirements for starting up an HCT unit,
however, the eventual goal of institutional leadership
should be towards acquiring Level III care provision
essentials.
An important aspect for establishment of a new HCT pro-
gram to be considered along with initial capital is sustain-
ability costs, particularly for quality maintenance. Let us
take the example of HEPA filters. There is an initial cost
of instalment of each unit for these filters, then there are
maintenance costs, air conditioning systems and electricity
costs; lastly, there may be costs associated with inspection
and certification of HEPA filters. Manpower, training of
ancillary and core staff, establishing standard operating
procedures, and lean processes for each avenue of a new
program also add tremendous costs to a new unit.
Like many industries in which the risks of sustainability
are great, an HCT unit establishment should be a very well
thought out decision, preferably with some input (or direct
involvement) with the governmental agencies, especially in
developing countries. The essential questions in establish-
ment are provided in Table 2, the most important of which
are the exact needs, capital, leadership, and capacity. All
the essential questions need to be answered before embark-
ing on HCT center establishment. A key aspect is the num-
ber of beds allocated for HCT recipients, as the initial
costs in setting up a tertiary care unit may range from few
thousand US$ per bed to more than a million US$ per bed,
depending on a number of factors.
Table 1 Worldwide Network for Blood and Marrow Transplantation (WBMT) levels of care for establishment of hematopoietic
cell transplant (HCT) center.
Level I
Minimum
Level II
Preferred
Level III
Ideal
Inpatient unit Clean single bedded rooms with
isolation capability
HEPA filtered positive pressure
rooms preferably with ante-room
(s)
Standalone HEPA filtered unit
with positive pressure rooms
Outpatient clinic Single patient examination rooms HEPA filtered unit with day
infusion unit
Intensive care unit ICU with positive/negative
pressure isolation rooms and
ventilator support
Level III ICU with capabilities for
hemodialysis/Continuous Veno-
Venous Hemofiltration/
Extracorporeal membrane
oxygenation
HEPA = high-efficiency particulate air; ICU = intensive care unit.
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Table 2 Costs and quality essentials in establishing a hematopoietic cell transplant (HCT) center.
Description Availability and challenges Potential solutions
Needs Exact needs of HCT should be assessed, e.g.,
most prevalent indications of HCT in a country;
demographic analysis; economic analysis
Inaccuracy of data; incomplete data; absence of
guidance in assessing needs and developing
feasibility reports
Thorough needs assessments by transplant
community along with referring specialists.
Obtaining accurate epidemiologic data with
the help of governmental or
nongovernmental organizations. Professional
consultations with management consultancy
firms if affordable
Capital needed Assessment of exact monetary amount needed
for startup and sustainability costs. Number of
inpatient beds is one of most important long
term drivers of both direct and indirect costs
given the specialized bed units needed for HCT
Quality assessments and quality improvement
programs may not be routinely incorporated in
initial capital costs. All aspects not accounted
for initially (e.g., hospital engineering for
positive pressure ventilated rooms; HLA typing
facilities; optimum blood bank facility, etc.)
Cost-utility and cost-benefit analyses for most of
the clinical management aspects are lacking
Quality checklists for hospital management
to be included in initial capital. Start up HCT
program priorities should be well defined
with input from multiple experts both within
and outside the institution (e.g., whether to
start up with allogeneic vs. autologous HCT
program; to start up with matched sibling
donor program first but should have a clear
plan for next step in near future for next
donor source, e.g., unrelated donor, cords or
haplos)
Leadership and expertise HCT is a highly specialized field, and for startup
programs should have experienced personnel
well trained in this field. Applies to physicians,
nurses, technicians, and all other allied health
staff
Lack of HCT expertise. Hematologists without
adequate HCT training or expertise are
frequently available in most of the developing
countries. However, for initiation of a new HCT
program, experienced and well trained
transplant physicians and nurses are essential for
the program’s success
Focus on human resources in acquiring
adequate well trained and experienced staff
with expertise in HCT. This applies to both
nursing and physician work force.
Quality and sustainability Quality of a program consists of many avenues:
(1) Quality of patient care (includes safety)
(2) Quality control procedures of laboratory
(3) Value determinants as proxy for quality of a
program, e.g., clinical outcomes, PROMs
Maintaining quality of an HCT program requires
additional human resource services for staffing,
information technology tools, error monitoring,
and damage control programs which can lead to
higher costs
For sustainability of a new HCT program, the
leadership, entrepreneurs (and/or venture
capitalists) and governmental authorities
should be convinced that focus on quality is
essential in HCT given the high stakes of this
tertiary care service. WBMT
recommendations should be taken into
account for the planning of a start-up
program. ‘‘Twinning” or ‘‘pairing” strategies
should be utilized for continuous advice over
a period of years (e.g., 5 year contract/
Memorandum of Understanding) with
experienced HCT programs in other countries
Compliance measurement tools should
ideally be automated to prevent errors which
can translate into huge cost-savings
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If needs assessment is incomplete or inaccurate, then
professional consultancy groups, which are the management
consulting firms, should be involved for advice, preferably
with those firms who have experience in preparing compre-
hensive data reports for business in developing countries.
This initial investment in management companies to have
an accurate feasibility report for establishing a tertiary care
center may actually be cost-saving in the long run, and
moreover, they can continue to provide professional advice
on many management aspects, e.g., experience curves and
business matrices, which can help in hospital
administration.
Quality control in HCT
Delineation of quality control (QC) and quality improvement
(QI) measures should be an essential requirement of HCT
programs in order to improve outcomes. The QC principles
should be thoroughly documented in the hospital policies
and measurement of compliance itself should be monitored
at well-defined intervals. One of the goals of HCT programs
should be eventual recognition by international societies
which provide accreditation to the HCT program. The two
large professional societies providing guidance for accredi-
tation and eventual certification include Joint Accreditation
Committee-International Society for Cellular Therapy &
European Society for Blood and Marrow Transplantation
(JACIE) and the Foundation for the Accreditation of Cellular
Therapy (FACT). Together, both societies/organizations
have assimilated the international standards for HCT pro-
grams which give guidance to HCT programs in all clinical
and technical matters [8].
Quite often, the question arises as to whether having an
internationally accredited program impacts on the out-
comes of an HCT program or not. Recent data suggests that
obtaining accreditation via JACIE compared to not having
any international accreditation results in a superior
relapse-free survival (hazard ratio 0.85; 0.75–0.95) and
overall survival (hazard ratio 0.86; 0.76–0.98) in allogeneic
transplant recipients [9]. Thus, it is advisable that one of
the planning aims of HCT programs should be towards
acquiring FACT-JACIE standards, with the eventual goal of
obtaining, and then maintaining certification. It is under-
stood that this would not be possible for a start-up program;
however, planning to obtain FACT-JACIE certification takes
years and is an important aspect for both patient safety
and for maintaining quality of an HCT program.
Costs versus quality for a new HCT program
The relationship of costs and quality in a healthcare setting
is very complex, as an abundance of variables which define
value and quality play a role. Although the notion that
reduction of costs is inversely proportional to the quality
performance and QC, it may not be true in the long run
when it comes to sustainability. Since a ‘‘low cost and high
quality” model is considered to be a Utopian phenomenon,
the leadership charged with development of a new program
should prioritize the avenues which require utmost capital,
while keeping an eye on QC.
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Recent (21st century) examples of new HCT center
establishment in developing countries include Nigeria and
Bangladesh, both of which have vastly distinct models of
HCT [10,11]. The annual GDP per capita (nominal) of both
the countries is under US$3000; moreover, the human
development index ranking of both countries is one of the
lowest globally, denoting extremely limited financial and
social resources. Lastly, the strategic priorities of fund allo-
cation are vastly different in different regions of the globe.
Nigeria initiated an allogeneic program first by transplanting
a pediatric patient with sickle cell disease (SCD), while a
Bangladesh program initiated the HCT unit by performing
an autologous HCT for an adult myeloma patient. While
these two approaches are widely different with respect to
the capital investments, risks of the procedure, age of the
recipient, and the indication for transplant, they exemplify
the practical real world issues in the HCT unit establishment
paradigm. Both programs at initiation had different reasons
for a start-up program for allogeneic versus autologous HCT,
e.g., in Nigeria, 2–3% of the population has SCD and since
no efficient national blood bank services exist, many
patients with SCD die early due to complications of SCD;
thus, it was appropriate for the Nigerians to think of estab-
lishing an allogeneic program despite the costs associated
with it, given the needs assessment of that country. Bangla-
desh, by contrast, had ample support from the federal gov-
ernment as well as from the Massachusetts General Hospital
to provide expertise at every level, including engineering of
the HCT unit, training the nursing staff, and above all, con-
stant guidance and availability on clinical aspects of trans-
plantation. Thus, they were justified in starting up an
autologous HCT program first, and future planning towards
starting allogeneic transplants.
In addition to governmental and institutional support,
nongovernmental organizations have also been proven to
help to establish HCT centers in developing countries. The
Cure2Children foundation is such a nongovernmental organi-
zation which has helped to initiate HCT for children with
thalassemia in India and Pakistan, while maintaining low
direct costs for an average cost of US$10,000 (Consumer
Price Index unadjusted) per HCT [7]. Additionally, many
countries which are in the process of setting up a new
HCT center have partnered with other countries with well-
established experienced HCT centers, to lower the costs
and to improve the quality of the HCT program, a concept
well-known in the field of healthcare as ‘‘twinning”.
Thus it all depends on the needs, eventual goals, and
resources when deciding on the balance for quality versus
costs for a start-up HCT program. Once the plan of estab-
lishing an HCT center is finalized based on needs assess-
ment, then the charter of the center should include the
basic aspects of value in healthcare which affect both costs
and quality, as depicted in Table 2.
Conclusions
There is an inarguable need for the establishment of HCT
centers in countries where the diseases for which HCT is
the only cure are endemic. In order to establish a new
HCT center, the vision of the leadership and the institu-
tional charters should include policies which place emphasis
on QC and QI in the long run. To lower the cost by compro-
mising quality will negate the purpose of HCT, since the out-
comes will be affected adversely. Minimal requirements of a
new HCT program should include the Level I recommenda-
tions by the WBMT. The eventual goal of a newly established
HCT program should be to improve quality and provide value
from an individual, institutional, and societal perspectives.
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